Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: A meta‐analysis
暂无分享,去创建一个
S. Resino | M. Jiménez-Sousa | A. Fernández-Rodríguez | M. Guzmán-Fulgencio | M. García-Álvarez | D. Pineda‐Tenor | M. Guzmán‐Fulgencio
[1] K. Chayama,et al. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial , 2014, Journal of viral hepatitis.
[2] V. Martel-Laferrière,et al. Hepatitis C Direct-acting Antiviral Agents: Changing the Paradigm of Hepatitis C Treatment in HIV-infected Patients , 2014, Journal of clinical gastroenterology.
[3] J. Cosín,et al. Vitamin D deficiency is associated with severity of liver disease in HIV/HCV coinfected patients. , 2014, The Journal of infection.
[4] J. D. del Campo,et al. Association between vitamin D and hepatitis C virus infection: a meta-analysis. , 2013, World journal of gastroenterology.
[5] C. Camma',et al. Association of vitamin D serum levels and its common genetic determinants, with severity of liver fibrosis in genotype 1 chronic hepatitis C patients , 2013, Journal of viral hepatitis.
[6] J. Agúndez,et al. Vitamin D deficiency and vitamin D therapy in chronic hepatitis C. , 2013, Annals of hepatology.
[7] W. Ibrahim,et al. Vitamin D levels in Egyptian HCV patients (genotype 4) treated with pegylated interferon. , 2013, Acta gastro-enterologica Belgica.
[8] G. Fattovich,et al. Vitamin A deficiency is associated with hepatitis C virus chronic infection and with unresponsiveness to interferon‐based antiviral therapy , 2013, Hepatology.
[9] C. Stokes,et al. Vitamin D in chronic liver disease , 2013, Liver international : official journal of the International Association for the Study of the Liver.
[10] A. Craxì,et al. How to optimize HCV therapy in genotype 1 patients: predictors of response , 2013, Liver international : official journal of the International Association for the Study of the Liver.
[11] A. Rieger,et al. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV–hepatitis C virus coinfected patients , 2013, AIDS.
[12] G. Silecchia,et al. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus , 2012, Hepatology.
[13] K. Schechtman,et al. Vitamin D and the racial difference in the genotype 1 chronic hepatitis C treatment response. , 2012, The American journal of clinical nutrition.
[14] G. Fattovich,et al. Vitamin D binding protein gene polymorphisms and baseline vitamin D levels as predictors of antiviral response in chronic hepatitis C , 2012, Hepatology.
[15] J. Souberbielle,et al. Low 25-hydroxyvitamin D serum levels correlate with the presence of extra-hepatic manifestations in chronic hepatitis C virus infection. , 2012, Rheumatology.
[16] Z. Kutalik,et al. A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C , 2012, PloS one.
[17] Assy Nimer,et al. Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients. , 2012, World journal of gastroenterology.
[18] A. Craxì,et al. 2011 European Association of the Study of the Liver hepatitis C virus clinical practice guidelines , 2012, Liver international : official journal of the International Association for the Study of the Liver.
[19] N. Chalasani,et al. Vitamin D Deficiency in Patients with Chronic Liver Disease and Cirrhosis , 2012, Current Gastroenterology Reports.
[20] Z. Fireman,et al. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. , 2011, World journal of gastroenterology.
[21] A. Branch,et al. Classical and emerging roles of vitamin D in hepatitis C virus infection. , 2011, Seminars in liver disease.
[22] S. Bhagani. Current treatment for chronic hepatitis C virus/HIV-infected individuals: the role of pegylated interferon-alpha and ribavirin. , 2011, Current opinion in HIV and AIDS.
[23] F. Negro,et al. Role of Hepatitis C virus genotype 3 in liver fibrosis progression – a systematic review and meta‐analysis , 2011, Journal of Viral Hepatitis.
[24] F. Carrat,et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. , 2011, Journal of hepatology.
[25] M. Ghany,et al. An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases , 2011, Hepatology.
[26] S. Reif,et al. Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats , 2011, Gut.
[27] C. Gordon,et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.
[28] G. Fattovich,et al. Complementary role of vitamin D deficiency and the interleukin‐28B rs12979860 C/T polymorphism in predicting antiviral response in chronic hepatitis C , 2011, Hepatology.
[29] S. Antinori,et al. Liver-related factors associated with low vitamin D levels in HIV and HIV/HCV coinfected patients and comparison to general population. , 2011, Current HIV research.
[30] F. Takeuchi,et al. Association of genetic variants for susceptibility to obesity with type 2 diabetes in Japanese individuals , 2011, Diabetologia.
[31] M. Pirisi,et al. Vitamin D supplementation improves response to antiviral treatment for recurrent hepatitis C , 2011, Transplant international : official journal of the European Society for Organ Transplantation.
[32] S. Nair,et al. Prevalence of Vitamin D Deficiency in Chronic Liver Disease , 2010, Digestive Diseases and Sciences.
[33] K. Badenhoop,et al. Vitamin D deficiency and a CYP27B1–1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy , 2010 .
[34] A. Stang. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses , 2010, European Journal of Epidemiology.
[35] C. Geisler,et al. Vitamin D controls T cell antigen receptor signaling and activation of human T cells , 2010, Nature Immunology.
[36] G. Marchesini,et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon‐based therapy in genotype 1 chronic hepatitis C , 2010, Hepatology.
[37] N. Theise. Liver biopsy assessment in chronic viral hepatitis: a personal, practical approach , 2007, Modern Pathology.
[38] Raghu Kacker,et al. Random-effects model for meta-analysis of clinical trials: an update. , 2007, Contemporary clinical trials.
[39] Roger M Harbord,et al. A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints , 2006, Statistics in medicine.
[40] Colin W Shepard,et al. Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.
[41] T. Asselah,et al. Fibrosis and disease progression in hepatitis C , 2002, Hepatology.
[42] S. Thompson,et al. How should meta‐regression analyses be undertaken and interpreted? , 2002, Statistics in medicine.
[43] David R. Jones,et al. An illustrated guide to the methods of meta-analysis. , 2001, Journal of evaluation in clinical practice.
[44] P. Bedossa,et al. An algorithm for the grading of activity in chronic hepatitis C , 1996, Hepatology.
[45] K. Ishak,et al. Histological grading and staging of chronic hepatitis. , 1995 .
[46] P. Scheuer,et al. Classification of chronic viral hepatitis: a need for reassessment. , 1991, Journal of hepatology.
[47] R F Galbraith,et al. A note on graphical presentation of estimated odds ratios from several clinical trials. , 1988, Statistics in medicine.
[48] T. Oppé,et al. Vitamin D deficiency. , 1979, British medical journal.
[49] W. Haenszel,et al. Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.
[50] A. Branch,et al. Vitamin D for your patients with chronic hepatitis C? , 2013, Journal of hepatology.
[51] Christine L. Taylor,et al. Committee to Review Dietary Reference Intakes for Vitamin D and Calcium , 2011 .
[52] Niu Jun-q. Interpretation:An update on treatment of genotype 1 chronic hepatitis C virus infection:2011 practice guideline by the American Association for the Study of Liver Diseases , 2011 .
[53] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.
[54] A. Minihane,et al. Update on trans fatty acids and health: Position statement by the Scientific Advisory Committee on Nutrition (SACN) , 2007 .